On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled for the international Frontiers in Biomagnetic Particles conference in Asheville, North Carolina. Carried out by researchers from Imagion Biosystems, the University of New Mexico, and Sandia National Laboratories, the study demonstrated the use of superparamagnetic relaxometry (SPMR) for specific detection of HER2 positive tumors in mice. The results suggest the utility of SPMR for sensitive and specific detection of cancer, and represent another successful step in the progression of Imagion Biosystems technology. Download the abstract of Dr. Vreeland’s presentation.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce